Immunotherapy (Checkpoint Inhibitor)

28 molecules in this therapeutic area. Open any product for its details, or send an inquiry directly.

Connect With Us

Immunotherapy (Checkpoint Inhibitor) (28)

Quick filters: Solid Tumour Hematologic Both Name A-Z Name Z-A

Therapeutic Areas

Sort by

Molecule	Drug Class / Mechanism	Oncology Type
Cemiplimab	Anti-PD-1 mAb	Both (Solid & Hematologic)
Molecule Cemiplimab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Cosibelimab	Anti-PD-L1 Monoclonal Antibody	Solid Tumour
Molecule Cosibelimab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-PD-L1 Monoclonal Antibody
Dostarlimab	Anti-PD-1 mAb	Both (Solid & Hematologic)
Molecule Dostarlimab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Envafolimab	Anti-PD-1 mAb	Both (Solid & Hematologic)
Molecule Envafolimab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Fianlimab	Anti-LAG-3 mAb	Solid Tumour
Molecule Fianlimab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-LAG-3 mAb
Ieramilimab	Anti-LAG-3 mAb	Solid Tumour
Molecule Ieramilimab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-LAG-3 mAb
Penpulimab	Anti-PD-1 mAb	Both (Solid & Hematologic)
Molecule Penpulimab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Pucotenlimab	Anti-PD-1 mAb	Both (Solid & Hematologic)
Molecule Pucotenlimab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Retifanlimab	Anti-PD-1 mAb	Both (Solid & Hematologic)
Molecule Retifanlimab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Serplulimab	Anti-PD-1 mAb	Both (Solid & Hematologic)
Molecule Serplulimab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Sintilimab	Anti-PD-1 mAb	Both (Solid & Hematologic)
Molecule Sintilimab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Tislelizumab	Anti-PD-1 mAb	Both (Solid & Hematologic)
Molecule Tislelizumab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb

Cemiplimab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Cosibelimab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-PD-L1 Monoclonal Antibody
Dostarlimab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Envafolimab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Fianlimab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-LAG-3 mAb
Ieramilimab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-LAG-3 mAb
Penpulimab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Pucotenlimab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Retifanlimab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Serplulimab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Sintilimab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Tislelizumab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb

‹ 1 2 3 ›

Product Range

Company

Global Network

Immunotherapy (Checkpoint Inhibitor)

Immunotherapy (Checkpoint Inhibitor) (28)

Cemiplimab

Cosibelimab

Dostarlimab

Envafolimab

Fianlimab

Ieramilimab

Penpulimab

Pucotenlimab

Retifanlimab

Serplulimab

Sintilimab

Tislelizumab

Cemiplimab

Cosibelimab

Dostarlimab

Envafolimab

Fianlimab

Ieramilimab

Penpulimab

Pucotenlimab

Retifanlimab

Serplulimab

Sintilimab

Tislelizumab